Secondary glaucoma: Toward interventions based on molecular underpinnings

Abstract

Glaucoma is a heterogeneous group of progressive diseases that leads to irreversible blindness. Secondary glaucoma refers to glaucoma caused by a known underlying condition. Pseudoexfoliation and pigment dispersion syndromes are common causes of secondary glaucoma. Their respective deposits may obstruct the trabecular meshwork, leading to aqueous humor outflow resistance, ocular hypertension, and optic neuropathy. There are no disease‐specific interventions available for either. Pseudoexfoliation syndrome is characterized by fibrillar deposits (pseudoexfoliative material) on anterior segment structures. Over a decade of multiomics analyses taken together with the current knowledge on pseudoexfoliative glaucoma warrant a re‐think of mechanistic possibilities. We propose that the presence of nucleation centers (e.g., vitamin D binding protein), crosslinking enzymes (e.g., transglutaminase 2), aberrant extracellular matrix, flawed endocytosis, and abnormal aqueous‐blood barrier contribute to the formation of proteolytically resistant pseudoexfoliative material. Pigment dispersion syndrome is characterized by abnormal iridolenticular contact that disrupts iris pigment epithelium and liberates melanin granules. Iris melanogenesis is aberrant in this condition. Cytotoxic melanogenesis intermediates leak out of melanosomes and cause iris melanocyte and pigment epithelium cell death. Targeting melanogenesis can likely decrease the risk of pigmentary glaucoma. Skin and melanoma research provides insights into potential therapeutics. We propose that specific prostanoid agonists and fenofibrates may reduce melanogenesis by inhibiting cholesterol internalization and de novo synthesis. Additionally, melatonin is a potent melanogenesis suppressor, antioxidant, and hypotensive agent, rendering it a valuable agent for pigmentary glaucoma. In pseudoexfoliative glaucoma, where environmental insults drive pseudoexfoliative material formation, melatonin's antioxidant and hypotensive properties may offer adjunct therapeutic benefits.This article is categorized under: Neurological Diseases > Molecular and Cellular Physiology

The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina

“…Its strong ability to suppress melanin production, its antioxidant properties, and its capacity to lower intraocular pressure make it a valuable treatment for this condition. In cases of pseudoexfoliative glaucoma, where environmental factors contribute to the development of pseudoexfoliative material, melatonin’s antioxidant and pressure-lowering characteristics may provide additional therapeutic advantages [ 160 ].…”

Appropriate patient population for future visual system axon regeneration therapies

“…When combined, the number of military personnel and civilians with TON-induced secondary glaucoma is estimated to be more than 40 million worldwide, rendering it a huge social and economic burden (Kang & Tanna, 2021). Glaucoma broadly is divided in two anatomic categories: angle closure and open angle, depending upon whether the angle between iris and cornea is 15 0 or larger (Mueller et al, 2023). They are characterized secondary if a prior disease or injury can be clearly ascribed to its onset or primary if no such clear association can be established.…”